Cargando…
GM-CSF targeting in COVID-19: an approach based on fragile foundations
Trials of anti-GM-CSF therapies in COVID-19 show divergent results; this may be explained by underlying biology and the fragility of the study findings. Further investigation of the pathophysiology of COVID-19 is required to better target therapies. http://bit.ly/3O1AuIo
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Respiratory Society
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9686318/ https://www.ncbi.nlm.nih.gov/pubmed/36396141 http://dx.doi.org/10.1183/13993003.02091-2022 |
| Sumario: | Trials of anti-GM-CSF therapies in COVID-19 show divergent results; this may be explained by underlying biology and the fragility of the study findings. Further investigation of the pathophysiology of COVID-19 is required to better target therapies. http://bit.ly/3O1AuIo |
|---|